PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.\', \'Department of Data Science, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; and.\', \'Department of Cellular Therapies Quality Assurance and.\', \'Stem Cell Transplant Donor Services, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1182/bloodadvances.2020003883
?:hasPublicationType
?:journal
  • Blood advances
is ?:pmid of
?:pmid
?:pmid
  • 33560397
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all